RECURSION PHARMACEUTICALS-A (RXRX) Stock News
NASDAQ:RXRX - Nasdaq - US75629V1044 - Common Stock - Currency: USD
RXRX Latest News, Press Relases and Analysis
The market is filled with gapping stocks in Friday's session.
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Wondering what's happening in today's after-hours session?
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
Chart Industries, Inc. (GTLS): A Bull Case Theory
We came across a bullish thesis on Chart Industries, Inc. (GTLS) on Twitter by LTVresearch. In this article, we will summarize the bulls’ thesis on GTLS. Chart Industries, Inc. (GTLS)’s share was trading at $128.45 as of April 17th. GTLS’s trailing and forward P/E were 30.80 and 10.91 respectively according to Yahoo Finance. Chart Industries (GTLS) presents […]
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?
Mentions: NVDA
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
/PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ:...
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News
Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”
We recently published a list of Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC’s Squawk on the Street, Jim […]
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX
Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.
Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week?
We recently published a list of 10 Firms Defy Market Slump, Record Double-Digit Gains Last Week. In this article, we are going to take a look at where Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stands against other firms that defied the market slump and recorded double-digit gains last week. The stock market may have taken a beating […]
Why STMicroelectronics NV (STM) Surged On Friday?
We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are going to take a look at where STMicroelectronics NV (NYSE:STM) stands against other Friday’s top performing stocks. The stock market finished the trading week on a positive note, wiping out earlier losses on Friday, as […]
Why Kingsoft Cloud Holdings Limited (KC) Surged On Friday?
We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are going to take a look at where Kingsoft Cloud Holdings Limited (NASDAQ:KC) stands against other Friday’s top performing stocks. The stock market finished the trading week on a positive note, wiping out earlier losses on Friday, […]
Why Summit Therapeutics Inc. (SMMT) Surged On Friday?
We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other Friday’s top performing stocks. The stock market finished the trading week on a positive note, wiping out earlier losses on Friday, […]
Why Certara Inc. (CERT) Surged On Friday?
We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against other Friday’s top performing stocks. The stock market finished the trading week on a positive note, wiping out earlier losses on Friday, as […]
Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday?
We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday’s top performing stocks. The stock market finished the trading week on a positive note, wiping out earlier losses on Friday, as […]
Mentions: NVDA
1 Magnificent S&P 500 Dividend Stock Down 33% to Buy and Hold Forever
This stock yields 6% and could be a genius buy in this volatile market.
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding...
Should You Buy Intuitive Machines Stock While It's Trading Below $8?
It's been just over a year since Intuitive Machines (NASDAQ: LUNR) made history as the first private company to achieve a successful lunar landing. Despite a strong growth outlook fueled by several high-profile contracts, shares of Intuitive Machines have cratered at the start of 2025, trading down 60% year to date at the time of this writing amid the broader stock market sell-off. Intuitive Machines does not launch rockets itself but instead designs, builds, and operates spacecraft, such as its lunar landers.
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side...
Recursion to Participate in Upcoming Investor Conference
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
All three companies are early-stage biotechnology companies working on next-generation therapeutics with advanced technologies. Over the weekend, Dr. Peter Marks, who headed the FDA's Center for Biologics Evaluation and Research, as well as its vaccine division, resigned in protest.
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Artificial intelligence (AI) is changing the world. Corporations are racing to establish themselves as leaders in the field, while investors want to cash in by putting their hard-earned money into the most promising AI companies. Two AI healthcare stocks -- Recursion Pharmaceuticals (NASDAQ: RXRX) and Teladoc Health (NYSE: TDOC) -- have lagged the market over the past year.
Mentions: TDOC
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy.
